Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies
Author Department
Surgery
Document Type
Other
Publication Date
6-2022
Recommended Citation
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2022 Jun 8. doi: 10.1038/s41433-022-02130-2. Epub ahead of print. Erratum for: Eye (Lond). 2022 May 21.
PMID
35676464
COinS